Similarly, the 6th and 7th Edition European School of Oncology‐European Society for Medical Oncology (ESO‐ESMO) International Consensus Guidelines: Advanced Breast Cancer (ABC6/7) suggest that, for patients previously treated with AIs who are maintaining appropriate glycosylated hemoglobin (HbA1c) levels, alpelisib combined with fulvestrant remains a viable treatment option for tumors with PIK3CA mutations in exon 9 or 20 [50]. Here, PIK3CA is linked to breast carcinoma.